Taiho Pharmaceutical Obtains Rights To Cancer Drug Yondelis From Spanish PharmaMar
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Japanese drug maker Taiho Pharmaceutical March 31 signed a license agreement with Spain's PharmaMar SA on anticancer compound Yondelis (trabectedin). According to the agreement, Taiho obtained exclusive rights to develop and market in Japan. PharmMar receives an initial payment of ¥1 billion, as well as future payments and sales royalties in Japan. Taiho will also cover all development and marketing costs of Yondelis in Japan. Taiho is planning to start Phase I trials for Yondelis to treat soft tissue sarcoma and cervical cancer in Japan. (Click here for more - Japanese language